The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on the Directed Share Issue of 2,601,732 shares at a subscription price of SEK 14.99 per share. Investors participating in the Directed Share Issue are mainly Flerie Invest AB and certain other existing and new investors with pronounced long-term interests in the Company, including Lars Stenlund and Torgny Stigbrand. An Extraordinary General Meeting in Lipum resolved on October 12, 2022 to approve the Board of Directors’ previous resolution on the Directed Share Issue. The Directed Share Issue has now been fully subscribed.
See the separate press release from September 22, 2022 for more information about the Directed Share Issue.
Erik Penser Bank is financial adviser and Mannheimer Swartling Advokatbyrå is legal adviser to Lipum in connection with the Directed Share Issue.
For further information please contact:
Einar Pontén, CEO
Mobile: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The Company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The Company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.